The Respiratory Disease Branch of the Chinese Medical Association was established in 2005.

At the end of 2005, under the advocacy and active promotion of Zhong Nanshan, President of the Chinese Medical Association, the Chinese Medical Association launched and established the "Special Fund for Clinical Medical Research of the Chinese Medical Association".

The nearly 30 years since the establishment of the Respiratory Disease Branch of the Chinese Medical Association shows that the Respiratory Disease Branch adheres to the purpose of the General Conference, conscientiously implements and completes various academic tasks assigned by the General Conference, and has made significant contributions to promoting the academic development of the respiratory disease discipline.

Contribution; The Respiratory Disease Branch has been committed to cultivating young and middle-aged scholars for many years, promoting the continuous enrichment and growth of the team of respiratory disease academic circles, and has had a profound impact on the development of the discipline.

Organization Profile In order to mobilize the enthusiasm of doctors for clinical scientific research and solve problems in the prevention and treatment of chronic respiratory diseases, the Respiratory Disease Branch took the lead in establishing clinical scientific research funds. The first batch of scientific research funds were provided by AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim

Pharmaceutical companies have vigorously sponsored ***14 million yuan for clinical research on the prevention and treatment of chronic airway diseases.

In the process of carrying out the work of "Special Funds for Clinical Research on Chronic Respiratory Diseases", the Respiratory Disease Branch strictly abides by the provisions of the "Measures for the Management of Special Funds for Clinical Medical Research of the Chinese Medical Association". The project establishment and review procedures are open, fair and scientific, and the management measures are standardized.

,strict.

After the third review and final review meeting, the final 46 projects were selected as the first batch of scientific research projects in 2007.

Since the fund investment focuses on the prevention and treatment of chronic respiratory diseases at the grassroots level and has been highly praised by medical staff, the 2008 fund review of the Respiratory Disease Branch will continue.

In order to improve the overall level of respiratory doctors, the Respiratory Disease Branch has formulated and continuously modified diagnostic and treatment guidelines for related disciplines over the years based on the development of the discipline: "Guidelines for the Prevention and Treatment of Bronchial Asthma"; "Guidelines for the Diagnosis and Treatment of Cough" (Draft)

; "Implications of the 2006 Global Initiative for Asthma Prevention and Control on China's Asthma Prevention and Control Work"; "Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia"; "Expert Knowledge on the Diagnosis and Treatment of Pulmonary Fungal Diseases"; "Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease"

"Revised version; "Pulmonary Thromboembolism-Deep Vein Thrombosis Imaging Examination Procedures (Recommended Protocol)"; "Diagnostic Flexible Bronchoscopy Guidelines", etc.

Entrusted by the Ministry of Health, the Respiratory Disease Branch of the Chinese Medical Association organized and compiled the "Clinical Technical Operation Specifications" (Respiratory Disease Branch) and was published by the "People's Military Medical Press"; the "Clinical Diagnosis and Treatment Guidelines" (Respiratory Disease Branch) were compiled by

Published by "People's Medical Publishing House".